Dr. Nasser Al Khalifa

Dr. Nasser Al Khalifa is a consultant neurologist at Royal Bahrain Hospital — one of the Kingdom's leading private hospitals providing JCI-standard specialty care to Bahrain's population and neighboring communities. With 18 years of neurology practice, Dr. Al Khalifa has established himself as Bahrain's leading authority in multiple sclerosis and demyelinating diseases, alongside a comprehensive general neurology practice.

His MS clinic at Royal Bahrain Hospital is the most active in the Kingdom, managing Bahraini nationals and expatriates with relapsing-remitting and progressive forms of MS. He is experienced with all classes of disease-modifying therapies including the high-efficacy infusion agents (natalizumab, ocrelizumab) and oral medications, and provides the monitoring and risk stratification essential for safe long-term MS management. He also evaluates and treats neuromyelitis optica spectrum disorder and autoimmune encephalitis.

Beyond MS, Dr. Al Khalifa manages acute stroke within Royal Bahrain Hospital's stroke protocol, ensures timely thrombolysis for eligible patients, and runs a post-stroke clinic for secondary prevention and rehabilitation coordination. His general neurology practice covers epilepsy, Parkinson's disease, headache disorders, and peripheral neuropathy.

Dr. Al Khalifa trained in the United Kingdom and holds the MRCP (Neurology) and FEAN designations. He communicates in Arabic and English.

Dr. Al Khalifa obtained his MBBS from the Arabian Gulf University in Bahrain and completed Internal Medicine residency at Salmaniya Medical Complex. He undertook Neurology specialist training in the United Kingdom, completing his MRCP (Neurology) following rotations at teaching hospitals in the West Midlands NHS region. He completed an MS and Neuroimmunology Fellowship at the National Hospital for Neurology and Neurosurgery (Queen Square), London. He holds the FEAN (Fellow of the European Academy of Neurology) and is an ECTRIMS member.

Dr. Al Khalifa's MS practice encompasses diagnosis using McDonald criteria with MRI, CSF oligoclonal banding, and evoked potentials; and management with all approved disease-modifying therapies including platform injectables, oral agents, and high-efficacy infusion therapies. He performs JC virus antibody monitoring for natalizumab patients and manages infusion reactions and immunological complications. In stroke, he administers IV alteplase, coordinates neurovascular imaging, and manages secondary prevention with antiplatelet therapy, anticoagulation, and risk factor control. He performs and interprets EEG for epilepsy, EMG/NCS for peripheral neuropathy, and botulinum toxin for chronic migraine and dystonia.

Dr. Al Khalifa has published in the Bahrain Medical Bulletin, Multiple Sclerosis Journal, and Journal of Neurology on MS epidemiology in Bahrain and the Gulf, disease-modifying therapy outcomes, and stroke care quality. He participates in ECTRIMS registry studies and presents at the Bahrain Medical Society neurology symposia and the European Academy of Neurology annual conference.

Royal Bahrain Hospital serves Bahrain's domestic and expatriate population. Dr. Al Khalifa consults in Arabic and English. Video consultations are available for MS follow-up monitoring and neurological second opinions for patients from Saudi Arabia and other Gulf states who can travel easily to Manama.

Dr. Al Khalifa has received the Bahrain Medical Society Neurology Achievement Award and recognition from Royal Bahrain Hospital for his MS center program development. He serves on the Bahrain National Multiple Sclerosis Society advisory board and participates in Gulf neurology educational programs.